Vernakalant - Cardiome Pharma

Drug Profile

Vernakalant - Cardiome Pharma

Alternative Names: Brinavess; Kynapid; MK-6621; RSD-1235; vernakalant (IV); vernakalant (oral)

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiome Pharma
  • Developer Aspen Pharmacare; Cardiome Pharma
  • Class Anisoles; Antiarrhythmics; Cyclohexanes; Pyrrolidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Atrial fibrillation

Most Recent Events

  • 02 Nov 2017 Vernakalant licensed to ATCO Laboratories in Pakistan
  • 02 Nov 2017 Launched for Atrial fibrillation in South Africa (IV)
  • 30 Aug 2017 Efficacy data from a retrospective study in Atrial fibrillation presented at the Annual Congress of the European Society of Cardiology 2017 (ESC-Card-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top